argenex SE (NASDAQ:ARGX) Receives $1,158.61 Consensus Target Price from Analysts

argenex SE (NASDAQ:ARGX) has been given an average recommendation of “Moderate Buy” by the twenty-four research firms that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $1,158.6111.

ARGX has been the subject of several analyst reports. Royal Bank Of Canada upped their target price on argenex from $1,025.00 to $1,100.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. Morgan Stanley boosted their price objective on argenex from $1,230.00 to $1,250.00 and gave the stock an “overweight” rating in a report on Monday, August 31st. Wedbush reaffirmed an “outperform” rating and set a $1,150.00 price objective on shares of argenex in a research note on Thursday, September 3rd. HC Wainwright upped their price objective on shares of argenex from $940.00 to $1,202.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Finally, Bank of America raised their target price on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd.

argenex Price Performance

ARGX opened at $979.76 on Wednesday. The business has a 50 day moving average price of $936.77 and a two-hundred day moving average price of $849.48. The company has a market capitalization of $61.29 billion, a price-to-earnings ratio of 37.63, a price-to-earnings-growth ratio of 1.02 and a beta of 0.47. argenex has a 1-year low of $661.85 and a 1-year high of $1,072.75.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. Equities analysts expect that argenex will post 29.13 EPS for the current fiscal year.

Hedge Funds Weigh In On argenex

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC raised its position in shares of argenex by 0.9% in the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after acquiring an additional 12 shares during the period. Allworth Financial LP grew its holdings in argenex by 12.7% during the fourth quarter. Allworth Financial LP now owns 115 shares of the company’s stock valued at $97,000 after purchasing an additional 13 shares during the period. WPG Advisers LLC grew its holdings in argenex by 17.8% during the first quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after purchasing an additional 13 shares during the period. NewEdge Advisors LLC increased its stake in argenex by 2.8% in the first quarter. NewEdge Advisors LLC now owns 523 shares of the company’s stock valued at $382,000 after purchasing an additional 14 shares in the last quarter. Finally, Ballentine Partners LLC increased its stake in argenex by 4.4% in the fourth quarter. Ballentine Partners LLC now owns 517 shares of the company’s stock valued at $435,000 after purchasing an additional 22 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Company Profile

argenx SE is a global biopharmaceutical company focused on developing and commercializing antibody-based medicines for patients with severe autoimmune diseases. The company’s research is centered on its antibody engineering technologies, including the SIMPLE Antibody platform and NHance technology, which are designed to identify and enhance therapeutic antibodies.

argenx’s leading product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce disease-causing immunoglobulin G antibodies.